Pacific Biosciences of California, Inc. (NASDAQ:PACB) is set to announce second quarter earning results on Monday 3rd August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, PACB to report 2Q20 loss of $ 0.18 per share from revenue of $ 13.72 million.
For the full year, analysts anticipate top line of $ 83.10 million, while looking forward to loss of $ 0.53 per share bottom line.
Previous Quarter Performance
Pacific Biosciences of California, Inc. unwinded income for the first quarter of $ 0.01 per share, from the revenue of $ 15.60 million. The quarterly revenues reduced 27.91 percent compared with the same quarter last year. Street analysts expected Pacific Biosciences of California, Inc. to report loss of $ 0.16 per share on revenue of $ 20.07 million for the first quarter. The bottom line results beat street analysts by $ 0.17 or 106.25 percent, at the same time, top line results fell short of analysts by $ 4.47 million or 22.27 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Pacific Biosciences of California, Inc.
Stock Performance
According to the previous trading day, closing price of PACB was $ 3.73, representing a 69.55 % increase from the 52 week low of $ 2.20 and a 37.21 % decrease over the 52 week high of $ 5.94.
The company has a market capital of $ 574.67 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”PACB” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Pacific Biosciences of California, Inc. will be hosting a conference call at 4:30 PM eastern time on 3rd August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.pacb.com
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The companys single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes.
